Complications in 220 Patients with Cardiac Dysrhythmias Treated by Phased Direct Current Shock, and Indications for Electroconversion

LEON RESNEKOV AND LAWSON Mc Donald

From The Institute of Cardiology, National Heart Hospital, London W.1

Direct current shock is more effective than alternating current in the treatment of ventricular dysrhythmias (Lown et al., 1962) and is more effective than drug therapy in converting supraventricular dysrhythmias to sinus rhythm (McDonald, Resnekov, and O'Brien, 1964). Although earlier reports stressed the benign nature of the treatment (Lown, 1964; Morris et al., 1964), it has already been shown that it may lead to potentially serious complications (McDonald and Resnekov, 1965; Resnekov and McDonald, 1965). In this paper complications following the use of phased direct current (DC) shock, in the management of 220 consecutive patients with supraventricular dysrhythmias and ventricular tachycardia, are analysed.

SUBJECTS AND METHODS

Studies were made on 220 patients (Table I) with atrial fibrillation, atrial flutter, atrial tachycardia, and ventricular tachycardia who were treated with direct current shock by methods previously described (McDonald et al., 1964). If the patient was on digitalis, it was stopped for at least 24 hours before treatment. Light general anesthesia was used in all except 1 patient (Gilston, Fordham, and Resnekov, 1965). The 220 primary episodes of treatment were consecutive, and patients were not excluded because they were too ill. The duration of the dysrhythmia, the grade of the patient's disability, and the nature and severity of any underlying heart disease were noted at the time of clinical examination. A 12-lead electrocardiogram was recorded in every patient and chest radiographs taken. The cardiothoracic ratio (CTR%) (Danzer, 1919) was calculated and the size of the left atrium graded (Resnekov, 1965). The erythrocyte sedimentation rate (ESR) was measured by a modification of Westergren's technique (Dawson, 1960). Serum levels of the glutamic oxaloacetic transaminase were measured by the Sigma-Frankel technique (1956, 1961) and of the lactic dehydrogenase by the technique of Berger and Broida (1957, 1960); the levels of blood urea and serum electrolytes were estimated in all patients receiving diuretic therapy. In any patient who was receiving anticoagulant therapy a thrombotest (Owren, 1959) was used to establish that

TABLE I
DETAILS OF PATIENTS

<table>
<thead>
<tr>
<th>Heart disease</th>
<th>Atrial fibrillation</th>
<th>Atrial flutter</th>
<th>Atrial tachycardia</th>
<th>Ventricular tachycardia</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rheumatic:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Post-operative</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Not operated</td>
<td>86</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>89</td>
</tr>
<tr>
<td>Lone dysrhythmias</td>
<td>15</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiomyopathy</td>
<td>33</td>
<td>7</td>
<td>1</td>
<td>1</td>
<td>41</td>
</tr>
<tr>
<td>Ischemic</td>
<td>17</td>
<td>2</td>
<td></td>
<td>1</td>
<td>20</td>
</tr>
<tr>
<td>Congenital</td>
<td>16</td>
<td></td>
<td></td>
<td>2</td>
<td>25</td>
</tr>
<tr>
<td>Treated thyrotoxicosis</td>
<td>7</td>
<td>11</td>
<td>4</td>
<td>6</td>
<td>22</td>
</tr>
<tr>
<td>Systemic hypertension</td>
<td>5</td>
<td></td>
<td></td>
<td>1</td>
<td>5</td>
</tr>
<tr>
<td>Digitalis toxicity</td>
<td>1</td>
<td></td>
<td>1</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Total</td>
<td>180</td>
<td>24</td>
<td>9</td>
<td>7</td>
<td>220</td>
</tr>
</tbody>
</table>

Received March 21, 1967.
the level of control was satisfactory. On the day following treatment, clinical examination, electrocardiogram, chest radiographs, and laboratory tests were repeated, and subsequently if they were abnormal.

RESULTS
Sinus rhythm was restored in 193 patients (88%). The successfully treated patients included 154 of 180 (86%) with atrial fibrillation, all 24 (100%) with atrial flutter, 8 of 9 with atrial tachycardia, and all 7 with ventricular tachycardia.

Complications occurred in 32 patients (14.5%)—see Table II. Transient rhythm disturbances, which were noted immediately after the shock in 53 per cent, and superficial skin burns, which occurred in 5 per cent, have been excluded.

Serum Enzyme Levels. Significant increases in the serum enzyme levels of glutamic oxaloacetic transaminase and lactic dehydrogenase after treatment were observed in 20 patients (Table II); all except one had had atrial fibrillation. The underlying heart disease was post-operative rheumatic heart disease in 7, cardiomyopathy in 4 (3 alcoholic), and chronic ischaemic heart disease in 3. No underlying heart disease could be determined in 6 (“lone” dysrhythmias).

A shock of 300–400 joules was used for conversion in 14 of the 20 patients, 200–300 joules in 3, and 50–150 joules in 3. An increase in the serum enzyme levels was observed as an isolated complication in 10 patients and was associated with other complications in 10 patients; they usually returned to pretreatment levels by five days, and always by seven days, after DC shock.

Increase in Heart Size and Pulmonary Oedema. A significant increase in the cardiothoracic ratio after treatment (Fig. 1) was found in 7 patients (Table II) and averaged 4 per cent (limits 1–6%). The increase in heart size was invariably associated with pulmonary venous congestion on chest radiographs, and frank pulmonary oedema occurred in 2. Atrial fibrillation was present before DC shock in 6 and ventricular tachycardia in 8. The underlying heart disease was chronic ischaemic heart disease in 3, cardiomyopathy in 2 (1 alcoholic), rheumatic heart disease with moderate mitral stenosis in 1, and corrected transposition with regurgitation of the systemic atrio-ventricular valve in 1. A shock of 300–400 joules was used for conversion in 5, 200 joules in 1, and 150 joules in 1. Additional complications were noted in 4 of the 7 patients; hypotension following the shock occurred in 2, significant increases in the levels of the serum enzymes in 3, and persistent multifocal ventricular ectopic beats in 1.

The increase in heart size usually persisted for one to two days, but always responded to bed-rest, digitalis, and diuretics.

Hypotension. Hypotension was defined as a systolic blood pressure of 80 mm. Hg or less for one hour or longer after electroconversion; it occurred in 7 patients, and was not present between induction of the anaesthesia and electroconversion. Atrial fibrillation was present before DC shock in 6
### TABLE II

COMPLICATIONS FOLLOWING DC SHOCK IN 32 OF 220 PATIENTS

<table>
<thead>
<tr>
<th>Patient No.</th>
<th>Disease</th>
<th>Rhythm</th>
<th>Maximum energy setting (joules)</th>
<th>Sinus rhythm rate</th>
<th>Anticoagulant cover</th>
<th>Enzyme level*</th>
<th>CTR %</th>
<th>Pulm. edema</th>
<th>Duration of hypotension (hr.)</th>
<th>ECG change</th>
<th>Embolism</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>SGOT</td>
<td>LDH</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>A</td>
<td>B</td>
<td>A</td>
<td>B</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>Lone</td>
<td>Atr. fib.</td>
<td>200</td>
<td>+</td>
<td>+</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>Mitral stenosis, post-op.</td>
<td>Atr. fib.</td>
<td>350</td>
<td>-</td>
<td>+</td>
<td>14</td>
<td>42</td>
<td>260</td>
<td>680</td>
<td>4</td>
<td>T ↓ V4-6</td>
<td>Pulm. infarction</td>
</tr>
<tr>
<td>10</td>
<td>Alcoholic cardiomyop.</td>
<td>Atr. fib.</td>
<td>250</td>
<td>+</td>
<td>+</td>
<td>22</td>
<td>38</td>
<td>480</td>
<td>660</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>Lone</td>
<td>Atr. fib.</td>
<td>400</td>
<td>+</td>
<td>+</td>
<td>20</td>
<td>70</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>Lone</td>
<td>Atr. fib.</td>
<td>400 (x 2)</td>
<td>-</td>
<td>+</td>
<td>21</td>
<td>60</td>
<td>225</td>
<td>680</td>
<td>1</td>
<td></td>
<td>3rd heart sound</td>
</tr>
<tr>
<td>14</td>
<td>Mitral stenosis, post-op.</td>
<td>Atr. fib.</td>
<td>400</td>
<td>-</td>
<td>+</td>
<td>36</td>
<td>51</td>
<td></td>
<td></td>
<td>3</td>
<td>T ↓ V3-6</td>
<td>3rd heart sound</td>
</tr>
<tr>
<td>27</td>
<td>Lone</td>
<td>Atr. fib.</td>
<td>400</td>
<td>-</td>
<td>+</td>
<td>21</td>
<td>168</td>
<td>110</td>
<td>800</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>36</td>
<td>Mitral stenosis, post-op.</td>
<td>Atr. fib.</td>
<td>400</td>
<td>-</td>
<td>+</td>
<td>16</td>
<td>65</td>
<td>190</td>
<td>200</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>41</td>
<td>Mitral stenosis</td>
<td>Atr. fib.</td>
<td>350</td>
<td>+</td>
<td>+</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>45</td>
<td>Lone</td>
<td>Atr. fib.</td>
<td>350</td>
<td>-</td>
<td>+</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>51</td>
<td>Mitral stenosis</td>
<td>Atr. fib.</td>
<td>150</td>
<td>+</td>
<td>+</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>68</td>
<td>Corrected transp. with regurgitation of AV valve</td>
<td>Atr. fib.</td>
<td>350</td>
<td>-</td>
<td>+</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>74</td>
<td>Mitral stenosis, post-op.</td>
<td>Atr. fib.</td>
<td>350</td>
<td>+</td>
<td>+</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>80</td>
<td>Cardiomyop.</td>
<td>Vent. tachy.</td>
<td>150</td>
<td>+</td>
<td>-</td>
<td>41</td>
<td>86</td>
<td>400</td>
<td>860</td>
<td>50</td>
<td>51</td>
<td>2</td>
</tr>
<tr>
<td>90</td>
<td>Aortic valvar disease, post-op.</td>
<td>Atr. fib.</td>
<td>150</td>
<td>+</td>
<td>+</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Cerebral</td>
</tr>
<tr>
<td>102</td>
<td>Ischemic heart disease, chronic</td>
<td>Atr. fib.</td>
<td>350</td>
<td>+</td>
<td>+</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>46</td>
<td>50</td>
</tr>
<tr>
<td>123</td>
<td>Mitral stenosis</td>
<td>Atr. fib.</td>
<td>350</td>
<td>+</td>
<td>+</td>
<td>18</td>
<td>40</td>
<td>190</td>
<td>680</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>129</td>
<td>Acute myoc. infarct.</td>
<td>Atr. tachy.</td>
<td>50</td>
<td>+</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Saddle</td>
</tr>
<tr>
<td>134</td>
<td>Acute myoc. infarct.</td>
<td>Vent. tachy.</td>
<td>50</td>
<td>-</td>
<td>+</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>138</td>
<td>Ischemic heart disease, chronic</td>
<td>Atr. fib.</td>
<td>400</td>
<td>+</td>
<td>+</td>
<td>32</td>
<td>55</td>
<td>170</td>
<td>500</td>
<td>48</td>
<td>53</td>
<td>Multifocal ectopic beats</td>
</tr>
<tr>
<td>142</td>
<td>Ischemic heart disease, chronic</td>
<td>Atr. fib.</td>
<td>200</td>
<td>+</td>
<td>+</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>48</td>
<td>54</td>
</tr>
<tr>
<td>155</td>
<td>Ischemic heart disease, chronic</td>
<td>Atr. fib.</td>
<td>200</td>
<td>+</td>
<td>+</td>
<td>18</td>
<td>430</td>
<td>118</td>
<td>500</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>169</td>
<td>Alcoholic cardiomyop.</td>
<td>Atr. fib.</td>
<td>300</td>
<td>-</td>
<td>37</td>
<td>620</td>
<td>63</td>
<td>600</td>
<td>50</td>
<td>53</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>175</td>
<td>Ischemic heart disease, chronic</td>
<td>Atr. fib.</td>
<td>200</td>
<td>+</td>
<td>+</td>
<td>60</td>
<td>540</td>
<td>87</td>
<td>1110</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>179</td>
<td>Mitr. regurg., post-op.</td>
<td>Atr. fib.</td>
<td>50</td>
<td>+</td>
<td>+</td>
<td>38</td>
<td>510</td>
<td>62</td>
<td>1010</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>190</td>
<td>Alcoholic cardiomyop.</td>
<td>Atr. fib.</td>
<td>400</td>
<td>-</td>
<td>-</td>
<td>24</td>
<td>370</td>
<td>48</td>
<td>540</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>196</td>
<td>Mitral stenosis, post-op.</td>
<td>Atr. fib.</td>
<td>400</td>
<td>-</td>
<td>+</td>
<td>22</td>
<td>500</td>
<td>44</td>
<td>700</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>199</td>
<td>Lone</td>
<td>Atr. fib.</td>
<td>350</td>
<td>+</td>
<td>+</td>
<td>29</td>
<td>260</td>
<td>&gt; 200</td>
<td>680</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>201</td>
<td>Mitral stenosis, post-op.</td>
<td>Atr. fib.</td>
<td>400</td>
<td>-</td>
<td>+</td>
<td>13</td>
<td>470</td>
<td>69</td>
<td>540</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>217</td>
<td>Mitral stenosis, post-op.</td>
<td>Atr. fib.</td>
<td>100</td>
<td>+</td>
<td>+</td>
<td>33</td>
<td>590</td>
<td>75</td>
<td>690</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>219</td>
<td>Ischemic heart disease, chronic</td>
<td>Atr. fib.</td>
<td>300</td>
<td>+</td>
<td>+</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Enzyme level in units. A, before, B after DC shock.
and ventricular tachycardia in 1. In 4 patients no underlying heart disease was detected; post-operative mitral stenosis was present in 1, corrected transposition in 1, and cardiomyopathy in 1. A shock of 350 or 400 joules was used in 5 patients, 200 in 1 and 150 joules in 1. Additional complications (Table II) occurred in 2 of the 7 patients.

None of the patients required sympathomimetic drugs to raise the blood pressure which always became normal within four hours.

**Electrocardiographic Changes.** Significant changes, other than temporary disturbances of rhythm, were noted in the electrocardiograms of 6 patients following electroconversion. T wave inversion (Fig. 2) was recorded in 5 patients and persistent multifocal ectopic beats (Fig. 3) in 1. Atrial fibrillation was the presenting dysrhythmia in all 6 patients and was apparently unassociated with underlying heart disease in 3; chronic ischaemic heart disease was present in 2, and post-operative rheumatic mitral stenosis in 1. A shock of 400 joules was used in 4 patients, 350 joules in 1, and 200 joules in 1. Additional complications were noted in 3 of the 6 patients (Table II). The electrocardiographic changes persisted for several days, and in 1 patient T wave inversion had remained up to 6 months.

**Pulmonary and Systemic Embolism.** Three patients developed embolism following DC shock (Table II). In the first patient, electroconversion under satisfactory anticoagulant control of “lone” atrial fibrillation (Evans and Swann, 1954) was achieved with 200 joules, and was followed on the day after treatment by inversion of the T wave in leads V4–6 and pleuritic pain. The chest radiograph showed linear atelectasis of the right lung.

---

**Fig. 2.**—Electrocardiogram of Patient 219 in atrial fibrillation before DC shock and one day after electroconversion. The T wave and S–T segment changes recorded after DC shock were associated with increases in the serum levels of glutamic oxaloacetic transaminase and lactic dehydrogenase.
FIG. 3.—Electrocardiogram leads V1 and V2 of Patient 138 recorded one day after the electroconversion of atrial fibrillation to sinus rhythm. Multifocal ectopic beats are recorded.

(Fig. 4), which appeared to be due to pulmonary infarction, from which a good recovery was made. The second patient had had an aortic valvotomy 6 months before DC shock, and developed attacks of paroxysmal atrial tachycardia 6 weeks after the electroconversion of her atrial fibrillation. A cerebral embolus, which resulted in hemiplegia, occurred at the time of changing rhythms. Anticoagulants were not being used at the time of cerebral embolus. The third patient, a man of 55 years, developed atrial tachycardia in association with a recent cardiac infarction. Sinus rhythm was established following a single shock of 50 joules. Anticoagulant therapy was not being given at the time. Six hours later a saddle embolus occurred at the bifurcation of the aorta. The circulation was re-established following surgical removal of the embolus within two hours of its occurrence, and the patient made an uneventful recovery.

Deaths Following Treatment. Death was directly or indirectly related to direct current shock in 4 patients.

Patient 51 had atrial fibrillation in association with moderate mitral stenosis and was brought into sinus rhythm with a shock of 150 joules. Subsequently he was given quinidine sulphate (B.P.), 300 mg. 6-hourly.

FIG. 4.—Chest radiograph of Patient 3: left, in atrial fibrillation, and right, one day later following the establishment of sinus rhythm by DC shock. Note linear atelectasis (arrowed) in sinus rhythm indicating pulmonary infarction.
Ventricular fibrillation developed 36 hours after the shock, and failed to respond to emergency resuscitative measures.

**Patient 90** died 7 months after the re-establishment of sinus rhythm. A cerebral embolus occurred 6 weeks after electroconversion and was followed by progressive cardiac and renal failure.

**Patient 134** was referred from a considerable distance because of a ventricular tachycardia which had followed cardiac infarction 9 days before. It was resistant to drug therapy. Cardiac arrest supervened while preparations were being made for direct current shock without anaesthesia. A single unsynchronized shock resulted in sinus rhythm, but 24 hours later cardiac arrest recurred and failed to respond to resuscitative measures.

**Patient 210** had atrial fibrillation in association with chronic ischaemic heart disease. Two weeks after the establishment of sinus rhythm, with a shock of 200 joules, bronchopneumonia developed and atrial fibrillation recurred. Death one day later was thought to be due to the toxic effects of the chest infection.

**Other Complications.** Two patients developed transient loud ventricular third heart sounds and one patient a loud atrial sound (Table II). In all 3 patients associated complications were noted.

**DISCUSSION**

Despite the claim that complications following DC shock would result only from drugs that were used to maintain sinus rhythm (Lown, 1964), the present series of patients demonstrates that complications from the DC shock may be expected in 14–5 per cent. Complications were multiple in 14 of the 32 patients.

Changes in the levels of the serum enzymes were the commonest complication, occurring either as an isolated finding or in combination with other complications (9%). These findings differ from those of Oram et al. (1963) who commented on the absence of raised enzyme levels following DC shock. In contrast, however, no fewer than 16 of 27 patients reported by Slodki et al. (1966) developed significant increases in the levels of serum enzymes. While raised levels of serum glutamic oxaloacetic transaminase do reflect myocardial damage (LaDue, Wróblewski, and Karmen, 1954), they could also indicate damage to skeletal muscle; raised levels of serum lactate dehydrogenase are more specific of myocardial damage (MacDonald, Simpson, and Nossal, 1957). It is significant that the raised levels of serum enzymes were frequently associated with other complications which could also be interpreted as evidence of myocardial damage (Table II). Furthermore, higher energy level settings of 300 joules or more were used in 70 per cent of the patients who were found to have raised serum enzymes following DC shock.

Pulmonary oedema and an increase in heart size following DC shock have been previously reported (Resnekov and McDonald, 1965), and confirmed (Honey, Nicholls, and Towers, 1965). This is not due to a sudden increase in the cardiac output with the establishment of sinus rhythm, for at rest the output of the heart is changed only slightly or not at all with the onset of sinus rhythm (Resnekov, 1965). Energy level settings of between 300 and 400 joules were used in 5 of the 7 patients, and significant changes in the levels of the serum enzymes or hypotension were often associated, suggesting that myocardial damage might be the cause. It is significant, however, that this complication occurs almost exclusively in those patients successfully reverted to sinus rhythm. Experimental work in dogs (L. Resnekov, P. Lord, G. E. Sowton, and J. Norman, 1965, unpublished data) has demonstrated considerable depression of mechanical function of the left atrium following direct current shock, and Logan et al. (1965) have shown that following electroconversion in man left atrial systole may be absent or inefficient despite normal "a" waves being recorded in the right atrium. It is possible, therefore, that this complication results in part from imbalance between right and left atrial function. Any additional obstruction to flow across the mitral valve or left ventricular dysfunction would tend to aggravate the situation and result in the development of pulmonary oedema (Bell, 1966). Of particular interest are the accounts of Broch and Müller (1957) who demonstrated an increase in the pulmonary capillary pressure following the quinidine conversion of atrial fibrillation, and of Hollman and Nicholson (1966) who reported the onset of severe pulmonary oedema which followed the spontaneous reversion to sinus rhythm of a 5-month episode of paroxysmal atrial fibrillation.

Acute breathlessness occurred in only 2 of the 7 patients, so that this complication may be overlooked unless chest radiographs are taken on the day following DC shock.

The embolic risk (1·4%) compares favourably not only with published reports of this complication following DC shock (Morris et al., 1964; Hurst et al., 1964; Paulk and Hurst, 1965; Navab and La Due, 1965), but also with an incidence of 2 per cent following quinidine conversion (Goldman, 1959–60). Where there is a clear risk of embolism or thrombosis, as in patients with recent cardiac infarction, chronic ischaemic heart disease, a malfunctioning mitral valve, cardiomyopathy, or previous history of embolism, anticoagulant therapy using a coumarin
derivative should be given, or heparin when the indication for DC shock is urgent. On the other hand, anticoagulant therapy for electroconversion does not appear to be necessary after successful mitral valvotomy or closure of an atrial septal defect.

Hypotension persisting for at least one hour following DC shock in 7 patients, and in 5 following the use of higher energy levels (350 or 400 joules), seems most likely to be associated with myocardial damage, as are the electrocardiographic changes that were found in the T waves. Significant T wave inversion (Fig. 2) occurred in 5 patients, and in 4, energy level settings of 350–400 joules were used. T wave changes and S–T segment elevation have also been recorded by Killip (1963), Oram and Davies (1964), Sussman, Wildenberg, and Cohen (1964), Turner and Towers (1964), and by Szekely, Batson, and Stark (1966). Multifocal ectopic beats (Fig. 3) persisting for 36 hours followed a DC shock with an energy level setting of 400 joules in a further patient.

Ventricular fibrillation directly related to DC shock has not occurred in the present series; it is likely that the cause of delayed ventricular fibrillation in Patient 51 (Table II) was due to quinidine, and in Patient 134 to a severe myocardial infarction. Killip (1963), Lemberg et al. (1964), and Towers et al. (1965) have all reported ventricular fibrillation immediately after DC shock. Failure of synchronization, with the shock occurring during the vulnerable phase of ventricular repolarization, has been considered as a cause, but over-digitalization may be responsible (Rabbino, Likoff, and Dreifus, 1964; Ross, 1964). Nachlas et al. (1966) consider that delivering too small a current to the heart by DC shock is the important precipitating factor rather than a failure in synchronization.

Of the 32 patients who developed complications following DC shock, 19 (60%) were given 300–400 joules, and a further 6 patients 200 joules. In the total series of 220 patients, 57 were treated with an energy level setting of 300–400 joules and 19 (33%) of these developed complications; 163 patients were treated with 50–250 joules and of these 13 (8%) developed complications. The difference between the 2 groups is highly significant (p < 0.001). This increased incidence of complications following higher energy level settings seems important and is shown in Fig. 5.

It has already been demonstrated (Peleška, 1961) that myocardial damage may result from a discharging capacitor. Unlike alternating current where the waveform is determined by the power station, the waveform and magnitude of a capacitor discharge may be varied considerably by changes in the design of the circuit. The important electrical variables which relate to the clinical use of DC shock are: the capacitance of the condenser; the value of the inductance of the circuit; the resistance between the patient electrodes; the rise time of the current waveform.

A capacitor of 16 microfarads charged to a DC voltage by a variable transformer is incorporated in the Lown cardioverter, which was used in the present study, and discharges through an inductance coil of 100 millihenrys and across the resistance of the body over a mean time of 3.5 milliseconds to produce the slightly underdamped waveform shown in Fig. 6. The essential difference between DC and AC defibrillation is that though DC develops many times the power of AC it expends much less energy in doing so. Furthermore, the heat which is generated in a patient is less with a DC shock (Tedeschi
and White, 1954), and ventricular function is less disturbed (Yarbrough, Ussery, and Whitley, 1964).

Patient electrodes should always be large enough to prevent excessive central current density (Peleška, 1958).

The effect on the heart of the passage of electrical energy depends on the current rather than on the voltage (Ferris et al., 1936), and this is true for both AC and DC shocks (Nachlas et al., 1966). Currents of less than 1 amp. may cause fibrillation while those exceeding 1.5 amp. will stop fibrillation (Kouwenhoven et al., 1957). Only 10–30 per cent of the total current passes through the heart when the shock is delivered to the chest wall (Guyton and Satterfield, 1951), and thus electrical energies of between 50 and 400 joules may be required to defibrillate through the chest wall.

The skin and tissue resistance is less important with DC defibrillators than with AC defibrillators, but nevertheless does vary from patient to patient. Furthermore, it is well established that the electrical impedance alters with higher voltages (Hopps, 1964) so that the value will not be constant in any one patient but will tend to lessen as the energy level is increased should sinus rhythm not follow the first shock. If the defibrillation apparatus is considered in terms of a DC resistive circuit (Fig. 7), resistance (R₁) between the inductance (L) and the body (R₂, R₃, R₄) may alter significantly because of a change in total body impedance, and this might be responsible for changes in the discharge waveform and in the current flowing across the heart.

It is clear, therefore, that even using apparatus of approved electrical design higher voltages and energies may cause changes that are outside the control of the operator.

The series of patients presented shows that complications are related to the higher energy level settings. Patients with atrial fibrillation of whatever cause persisting for more than 5 years have only a 48 per cent chance of achieving sinus rhythm; 75 per cent of these will revert to the dysrhythmia within a period of time varying from minutes to 9 months following electroconversion (Resnekov, 1965). The increased incidence of complications in those patients with atrial fibrillation of longer duration is shown in Fig. 8. It is doubtful, therefore, whether energy level settings in excess of 300 joules are justified in patients presenting with longstanding dysrhythmias. Nevertheless, hemodynamic benefit in sinus rhythm, especially on exercise, can be shown even in this group (Resnekov, 1965) so that each patient requires individual assessment. The higher energy level settings (300–400 joules) should only be used in those patients who have acute dysrhythmias resulting in serious hemodynamic consequences and where the re-establishment of sinus rhythm is urgently required. Although it might be considered that patients with lone atrial fibrillation, small hearts, and at most very slight left atrial enlargement, would be ideal for DC defibrillation, our experience with 33 patients suggests the contrary. In 21 per cent sinus rhythm was not established (compared with 12% of failures in the other groups), complications to DC shock were noted in 25 per cent, and only 4 patients have re-
mained in sinus rhythm for a significant length of time. Similarly, patients with atrial fibrillation in association with chronic ischaemic heart disease have a high incidence of complications following DC shock (37%), as do patients with atrial fibrillation in association with cardiomyopathy (17.5%—Table III).

When, in the management of cardiac dysrhythmias, a decision to restore sinus rhythm is made, phased direct current shock may at present be considered the method of choice for the following: in supraventricular and ventricular dysrhythmias requiring urgent treatment, including those following soon after myocardial infarction and cardiac operations; in atrial dysrhythmias following closure of atrial septal defects, which are often resistant to treatment with drugs; in atrial fibrillation following successful mitral valvotomy; in re-establishing sinus rhythm even if only to improve temporarily the haemodynamic state in mitral regurgitation, following the insertion of prosthetic or homograft valves, and where resistant cardiac failure is associated with an atrial dysrhythmia; in all cases of atrial flutter that have not readily returned to sinus rhythm with digitalis; and in atrial tachycardia which has not responded to simple measures such as vagal stimulation. In the above situations energy level settings of 50–400 joules may be used, in increments of 50 joules, and the outcome of treatment is satisfactory. However, in our experience, relapses are particularly frequent and complications are common, when phased direct current shock is used to treat chronic atrial fibrillation of more than 3 years’ duration, of whatever cause, atrial fibrillation in ischaemic heart disease, and atrial fibrillation in association with a cardiomyopathy. It is considered that energy level settings in these cases should not exceed 300 joules.

The treatment of "lone" atrial fibrillation by direct current shock has been particularly disappointing, and the method should probably be seldom used in such patients. Furthermore, it is not indicated in patients with rheumatic heart disease, unless the natural history of the disease has been altered by heart operation.

**Summary**

There were 220 consecutive patients with atrial dysrhythmias and ventricular tachycardia who were treated by phased direct current shock; complications followed in 14.5 per cent.

Increases in the serum levels of glutamic oxaloacetic transaminase and lactic dehydrogenase...
Electroconversion: Complications and Indications

occurred in 20 of the 220 patients, episodes of pulmonary oedema in 2, enlargement of the heart and pulmonary venous congestion in 7, electrocardiographic changes in 6, and pulmonary or systemic emboli in 3. Death was directly or indirectly related to direct current shock in 4 patients.

Complications were related to higher energy level settings especially those exceeding 300 joules. Patients most likely to develop complications were those with dysrhythmias in association with ischaemic heart disease and cardiomyopathy, and when atrial fibrillation of whatever cause was present for more than 3 years. Patients with lone atrial fibrillation and flutter also had a high incidence of complications.

Indications for phased direct current in the management of cardiac dysrhythmias are reviewed, and conclusions drawn regarding energy level settings to be used.

It is suggested that attempts should seldom be made to convert lone atrial fibrillation and flutter by direct current shock.

Important electrical variables in the apparatus for phased direct current shock are reviewed.

REFERENCES


Resnekov and McDonald


